Massihnia, Daniela Avan, Amir Funel, Niccola Maftouh, Mina van Krieken, Anne Granchi, Carlotta Raktoe, Rajiv Boggi, Ugo Aicher, Babette Minutolo, Filippo Russo, Antonio Leon, Leticia Peters, Godefridus Giovannetti, Elisa Additional file 1: Figure S1. of Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer PFS curves according to phospho-Akt expression in radically-resected PDACs, showing that patients with high and “very high” phospho-Akt (right panel) had a significantly worse PFS. Figure S2. Growth inhibitory effects after MK-2206 exposure in LPC006 (72-hours). Figure S3. Growth inhibitory effects after 72 hours exposure to perifosine, gemcitabine or their combination at a fixed ratio based on IC50 values in CFPAC-1 and PANC-1 cells. On the X-axis the drug concentrations for the combination are referred to gemcitabine. Figure S4. Phospho-Akt (serine residue-473) expression, normalized to total Akt, after 4-hour exposure, as determined by ELISA. Figure S5. A Phospho-Akt (serine residue-473) expression, normalized to total Akt, after 24-hour exposure. B Phospho-Akt (threonine residue-308) expression, normalized to total Akt, after 24-hour exposure, as determined by ELISA. Figure S6. Expression of gemcitabine determinants in PANC-1 cells treated with perifosine, as determined by qRT-PCR. Dashed line, values in untreated samples. Figure S7. Wound-healing assay in CFPAC-1 and PANC-1 exposed to perifosine, gemcitabine or their combination (IC50 values, 24 hours). Figure S8. Wound-healing assay in LPC006 exposed to MK-2206, gemcitabine or to their combination (IC50 values, 24 hours). Figure S9. Annexin-V assay in LPC028 and LPC006. Figure S10: Modulation of caspase-3, caspase-6/-8/ and caspase-9 in CFPAC-1 and PANC-1, as determined by a specific fluorometric assay. Figure S11. Cell growth inhibition in LPC006 cells after 72-hour exposure to MK-2205, NVP-BEZ235 at IC50 values, together with DMSO or with the Glut1 inhibitor PGL13, at 30 μM. Points, or Columns, mean values obtained from three independent experiments; bars, SEM. *Significantly different from controls. (PPTX 328 kb) Pancreatic ductal adenocarcinoma;Akt;Synergism;Gemcitabine 2017-01-06
    https://springernature.figshare.com/articles/presentation/Additional_file_1_Figure_S1_of_Phospho-Akt_overexpression_is_prognostic_and_can_be_used_to_tailor_the_synergistic_interaction_of_Akt_inhibitors_with_gemcitabine_in_pancreatic_cancer/4529255
10.6084/m9.figshare.c.3660389_D2.v1